292 related articles for article (PubMed ID: 19874262)
21. Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance.
Ponnusamy S; Meyers-Needham M; Senkal CE; Saddoughi SA; Sentelle D; Selvam SP; Salas A; Ogretmen B
Future Oncol; 2010 Oct; 6(10):1603-24. PubMed ID: 21062159
[TBL] [Abstract][Full Text] [Related]
22. Altering the sphingosine-1-phosphate/ceramide balance: a promising approach for tumor therapy.
Huwiler A; Pfeilschifter J
Curr Pharm Des; 2006; 12(35):4625-35. PubMed ID: 17168766
[TBL] [Abstract][Full Text] [Related]
23. Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells.
Holman DH; Turner LS; El-Zawahry A; Elojeimy S; Liu X; Bielawski J; Szulc ZM; Norris K; Zeidan YH; Hannun YA; Bielawska A; Norris JS
Cancer Chemother Pharmacol; 2008 Feb; 61(2):231-42. PubMed ID: 17429631
[TBL] [Abstract][Full Text] [Related]
24. Targeting ceramide metabolic pathway induces apoptosis in human breast cancer cell lines.
Vethakanraj HS; Babu TA; Sudarsanan GB; Duraisamy PK; Ashok Kumar S
Biochem Biophys Res Commun; 2015 Aug; 464(3):833-9. PubMed ID: 26188095
[TBL] [Abstract][Full Text] [Related]
25. Molecular targeting of acid ceramidase: implications to cancer therapy.
Zeidan YH; Jenkins RW; Korman JB; Liu X; Obeid LM; Norris JS; Hannun YA
Curr Drug Targets; 2008 Aug; 9(8):653-61. PubMed ID: 18691012
[TBL] [Abstract][Full Text] [Related]
26. Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity.
Realini N; Solorzano C; Pagliuca C; Pizzirani D; Armirotti A; Luciani R; Costi MP; Bandiera T; Piomelli D
Sci Rep; 2013; 3():1035. PubMed ID: 23301156
[TBL] [Abstract][Full Text] [Related]
27. Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate.
Mao C; Obeid LM
Biochim Biophys Acta; 2008 Sep; 1781(9):424-34. PubMed ID: 18619555
[TBL] [Abstract][Full Text] [Related]
28. Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancer.
Liu X; Elojeimy S; El-Zawahry AM; Holman DH; Bielawska A; Bielawski J; Rubinchik S; Guo GW; Dong JY; Keane T; Hannun YA; Tavassoli M; Norris JS
Mol Ther; 2006 Nov; 14(5):637-46. PubMed ID: 16887394
[TBL] [Abstract][Full Text] [Related]
29. Roles of bioactive sphingolipids in cancer biology and therapeutics.
Saddoughi SA; Song P; Ogretmen B
Subcell Biochem; 2008; 49():413-40. PubMed ID: 18751921
[TBL] [Abstract][Full Text] [Related]
30. Sphingolipids in cancer.
Furuya H; Shimizu Y; Kawamori T
Cancer Metastasis Rev; 2011 Dec; 30(3-4):567-76. PubMed ID: 22005951
[TBL] [Abstract][Full Text] [Related]
31. Acid ceramidase-mediated production of sphingosine 1-phosphate promotes prostate cancer invasion through upregulation of cathepsin B.
Beckham TH; Lu P; Cheng JC; Zhao D; Turner LS; Zhang X; Hoffman S; Armeson KE; Liu A; Marrison T; Hannun YA; Liu X
Int J Cancer; 2012 Nov; 131(9):2034-43. PubMed ID: 22322590
[TBL] [Abstract][Full Text] [Related]
32. Acid Ceramidase Depletion Impairs Neuronal Survival and Induces Morphological Defects in Neurites Associated with Altered Gene Transcription and Sphingolipid Content.
Kyriakou K; Lederer CW; Kleanthous M; Drousiotou A; Malekkou A
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111095
[TBL] [Abstract][Full Text] [Related]
33. Sphingolipids and acid ceramidase as therapeutic targets in cancer therapy.
Govindarajah N; Clifford R; Bowden D; Sutton PA; Parsons JL; Vimalachandran D
Crit Rev Oncol Hematol; 2019 Jun; 138():104-111. PubMed ID: 31092365
[TBL] [Abstract][Full Text] [Related]
34. Targeted Induction of Ceramide Degradation Leads to Improved Systemic Metabolism and Reduced Hepatic Steatosis.
Xia JY; Holland WL; Kusminski CM; Sun K; Sharma AX; Pearson MJ; Sifuentes AJ; McDonald JG; Gordillo R; Scherer PE
Cell Metab; 2015 Aug; 22(2):266-278. PubMed ID: 26190650
[TBL] [Abstract][Full Text] [Related]
35. The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy.
Saad AF; Meacham WD; Bai A; Anelli V; Elojeimy S; Mahdy AE; Turner LS; Cheng J; Bielawska A; Bielawski J; Keane TE; Obeid LM; Hannun YA; Norris JS; Liu X
Cancer Biol Ther; 2007 Sep; 6(9):1455-60. PubMed ID: 17881906
[TBL] [Abstract][Full Text] [Related]
36. Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications.
Morad SA; Cabot MC
Biochim Biophys Acta; 2015 Sep; 1851(9):1134-45. PubMed ID: 25964209
[TBL] [Abstract][Full Text] [Related]
37. Identification of a Novel Acid Sphingomyelinase Activity Associated with Recombinant Human Acid Ceramidase.
He X; Schuchman EH
Biomolecules; 2023 Nov; 13(11):. PubMed ID: 38002305
[TBL] [Abstract][Full Text] [Related]
38. Novel mechanisms of action of classical chemotherapeutic agents on sphingolipid pathways.
Hajj C; Becker-Flegler KA; Haimovitz-Friedman A
Biol Chem; 2015 Jun; 396(6-7):669-79. PubMed ID: 25719313
[TBL] [Abstract][Full Text] [Related]
39. C6-ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growth.
Flowers M; Fabriás G; Delgado A; Casas J; Abad JL; Cabot MC
Breast Cancer Res Treat; 2012 Jun; 133(2):447-58. PubMed ID: 21935601
[TBL] [Abstract][Full Text] [Related]
40. Neutral ceramidase encoded by the Asah2 gene is essential for the intestinal degradation of sphingolipids.
Kono M; Dreier JL; Ellis JM; Allende ML; Kalkofen DN; Sanders KM; Bielawski J; Bielawska A; Hannun YA; Proia RL
J Biol Chem; 2006 Mar; 281(11):7324-31. PubMed ID: 16380386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
